Merck Serono to sell portfolio of 30 B-MS drugs in Latin America

15 June 2008

Merck Serono, a division of Germany's Merck KGaA, has signed a distribution agreement with Bristol-Myers Squibb for a portfolio of established pharmaceutical brands in Latin America. Under the terms of the agreement, Merck Serono acquires exclusive rights to commercialize more than 30 prescription medicines, primarily focused on the cardiometabolic area, in seven Latin American countries. The US drugmaker's sales for this portfolio exceeded $90.0 million in 2007. Financial details of the agreement were not disclosed. The duration of the deal is limited to an initial period of three years, with the possibility of a further extension upon mutual agreement. The seven countries in Latin America covered by the deal are Argentina, Chile, Colombia, Ecuador, Panama, Peru and Venezuela. The portfolio includes well-known brands including Pravachol (pravastatin) for the treatment of elevated cholesterol levels and the off-patent hypertension drug Monopril (fosinopril). While Merck Serono will be the exclusive distributor of the portfolio, Bristol-Myers Squibb will remain responsible for the manufacture of the medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight